These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29673412)

  • 21. Diagnostic Assessment Reviews: is cost-effectiveness analysis helpful or necessary?
    Mistry H; Mason J
    J Health Serv Res Policy; 2018 Oct; 23(4):222-242. PubMed ID: 30309266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal.
    Morton A; Adler AI; Bell D; Briggs A; Brouwer W; Claxton K; Craig N; Fischer A; McGregor P; van Baal P
    Health Econ; 2016 Aug; 25(8):933-8. PubMed ID: 27374115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prioritisation of health technology assessment. The PATHS model: methods and case studies.
    Townsend J; Buxton M; Harper G
    Health Technol Assess; 2003; 7(20):iii, 1-82. PubMed ID: 13678549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
    Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
    Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.
    Edney LC; Haji Ali Afzali H; Cheng TC; Karnon J
    Pharmacoeconomics; 2018 Feb; 36(2):239-252. PubMed ID: 29273843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health economic evaluation: important principles and methodology.
    Rudmik L; Drummond M
    Laryngoscope; 2013 Jun; 123(6):1341-7. PubMed ID: 23483522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Why and how to monitor the cost and evaluate the cost-effectiveness of HIV services in countries.
    Beck EJ; Santas XM; Delay PR
    AIDS; 2008 Jul; 22 Suppl 1():S75-85. PubMed ID: 18664958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies.
    Love-Koh J; Cookson R; Gutacker N; Patton T; Griffin S
    Value Health; 2019 May; 22(5):518-526. PubMed ID: 31104729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating a cost-effectiveness threshold for the Spanish NHS.
    Vallejo-Torres L; García-Lorenzo B; Serrano-Aguilar P
    Health Econ; 2018 Apr; 27(4):746-761. PubMed ID: 29282798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methods for economic evaluation alongside a multicentre trial in developing countries: a case study from the WHO Antenatal Care Randomised Controlled Trial.
    Mugford M; Hutton G; Fox-Rushby J
    Paediatr Perinat Epidemiol; 1998 Oct; 12 Suppl 2():75-97. PubMed ID: 9805724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health economic evaluation in Japan: a case study of one aspect of health technology assessment.
    Oliver A
    Health Policy; 2003 Feb; 63(2):197-204. PubMed ID: 12543532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review of economic evaluations of CHW interventions aimed at improving child health outcomes.
    Nkonki L; Tugendhaft A; Hofman K
    Hum Resour Health; 2017 Feb; 15(1):19. PubMed ID: 28245839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The challenges of economic evaluations of remote technical health interventions.
    Kennedy CA
    Clin Invest Med; 2005 Apr; 28(2):71-4. PubMed ID: 15909483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic evaluation and the postponement of health care costs.
    van Baal PH; Feenstra TL; Polder JJ; Hoogenveen RT; Brouwer WB
    Health Econ; 2011 Apr; 20(4):432-45. PubMed ID: 21210494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Importance of Economic Evaluation in Health Care: An Indian Perspective.
    Dang A; Likhar N; Alok U
    Value Health Reg Issues; 2016 May; 9():78-83. PubMed ID: 27881265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'Health Economics' and the evolution of economic evaluation of health technologies.
    Hutton J
    Health Econ; 2012 Jan; 21(1):13-8. PubMed ID: 22147623
    [No Abstract]   [Full Text] [Related]  

  • 39. A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study.
    Lomas J; Schmitt L; Jones S; McGeorge M; Bates E; Holland M; Cooper D; Crowther R; Ashmore M; Rojas-Rueda D; Weatherly H; Richardson G; Bojke L
    BMJ Open; 2016 Jun; 6(6):e010686. PubMed ID: 27329439
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.